Table 1 Baseline characteristics of participants
| Â | Control NA= 12 | Intervention NB= 16 | P value (A-B) | |
|---|---|---|---|---|
Demographics | ||||
Age (y)1 | 81.8 (7.1, 71–94) | 85.1 (6.7, 70–98) | 0.233 | |
Gender | Male:Female | 5:7 | 7:9 | 0.609 |
Ethnicity | White British | 12 (100%) | 16 (100%) | - |
Care Home Type2 | N:R:D | 5:7:0 | 3:10:3 | 0.171 |
Body Mass Index1 | 25.5 (4.6, 20.8-36.4) | 27.7 (4.8, 19.5-35.9) | Â | |
Heart failure | ||||
Heart Failure3 | Confirmed:New | 6:6 | 9:7 | 1.000 |
NYHA4 class | I:II:III:IV | 5:4:1:1 | 10:1:4:1 | 0.213 |
Ejection Fraction (mean %, SD) | 43 (6.3) | 33 (1.4) | 0.146 | |
Total no of co-morbidities (mean, SD) 5 | 4.67 (2.1) | 4.50 (1.5) | 0.319 | |
Renal Function | ||||
Urea Abnormal6 | 8 (75%) | 9 (56%) | 0.705 | |
Creatinine Abnormal7 | 2 (17%) | 5 (31%) | 0.558 | |
Prescribed drugs 8 | ||||
ACEi and β blocker | 3 (25%) | 6 (38%) | 0.687 | |
ACEi | 6 (50%) | 7 (44%) | 1.000 | |
β blocker | 5 (42%) | 9 (56%) | 0.704 | |
Angiotensin Receptor Blocker | 0 (0%) | 0 (0%) | - | |
Calcium Channel Blocker | 1 (8%) | 4 (25%) | 0.355 | |
Diuretic | 8 (67%) | 9 (56%) | 0.705 | |
Statin | 7 (58%) | 8 (50%) | 0.718 | |
Digoxin | 4 (33%) | 1 (6%) | 0.133 | |
Antiplatelet | 7 (58%) | 10 (63%) | 1.000 | |
Spironolactone | 0 (0%) | 0 (0%) | - | |
Bronchodilators | 4 (33%) | 2 (13%) | 0.354 | |
Warfarin | 3 (25%) | 1 (6%) | 0.285 | |
Non Steroidal Anti-Inflammatory Drugs | 0 (0%) | 1 (6%) | 1.000 | |
Total no of prescribed drugs (mean, SD) | 10.3 (3.4) | 9.5 (4.7) | 0.287 | |